Apogee Therapeutics, a clinical‑stage biotechnology company focused on inflammatory and immunology therapies, completed a $300 million underwritten public offering of its common stock on March 23, 2026. The offering includes a 30‑day option for underwriters to purchase an additional $45 million of shares at the offering price, less underwriting discounts and commissions. Joint book‑running managers Jefferies, TD Cowen, Stifel and Guggenheim Securities, with lead managers Wedbush PacGrow and BTIG, oversaw the transaction, which was filed under a shelf registration statement dated August 12, 2024.
The proceeds, combined with the company’s $902.9 million in cash, cash equivalents and marketable securities as of December 31, 2025, will be allocated to advance its pipeline and support commercial readiness. Funding will cover preclinical studies, Phase 2 and Phase 3 clinical trials, manufacturing scale‑up, capital expenditures, working capital and general corporate purposes. The allocation reflects the company’s strategy to accelerate the development of its lead candidate, zumilokibart (APG777), for moderate‑to‑severe atopic dermatitis.
The offering follows a milestone in the company’s clinical program: positive 52‑week maintenance data from Part A of the Phase 2 APEX trial of zumilokibart. CEO Michael Henderson noted, “Our 52‑week Part A data mark a significant milestone for zumilokibart, with the potential to transform the treatment paradigm as the first 6‑month dosed therapeutic for patients with AD.” The data suggest durable disease control with less frequent dosing, positioning the drug against established biologics such as Dupixent and Ebglyss.
Apogee’s capital raise is consistent with its historical financing pattern. In October 2025 the company completed a roughly $300 million offering that closed with gross proceeds of about $345 million. The new offering provides additional liquidity to sustain the company’s R&D pipeline and to support the anticipated commercial launch of zumilokibart, which could generate significant revenue once approved. The financing also signals management’s confidence in the company’s growth trajectory and its ability to secure additional capital when needed.
The market’s reaction to the announcement was largely positive, driven by the strong clinical data and the company’s clear plan to use the proceeds to advance a promising therapy. Investors viewed the offering as a necessary step to fund the next phases of development rather than a sign of financial distress. The company’s robust cash position and the strategic use of the new capital reinforce its long‑term growth prospects.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.